Updated: Embattled Novo Nordisk considers buying a monthly GLP-1, unveils pipeline cuts
更新：陷入困境的诺和诺德考虑收购月用GLP-1注射剂，并公布管线削减

Novo Nordisk is looking into acquiring or developing a long-acting GLP-1 drug that could compete with Pfizer’s monthly obesity shot. It has also cut a handful of drugs from its pipeline, so it certainly has room to add more candidates.
诺和诺德正寻求收购或自主开发一种长效GLP-1药物，以与辉瑞的月用减重注射剂相竞争。它也从管线中砍掉了数款药物，因此显然有空间再加入更多候选品种。